Hairy Cell Leukemia · line 2 · Vemurafenib + rituximab for relapsed/refractory BRAF-V600E HCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-VEMURAFENIB-HCL-RELAPSED |
| ID | IND-HCL-2L-VEMURAFENIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-HCL |
| Sources | SRC-MOZ-UA-LYMPH-2013 SRC-NCCN-BCELL-2025 |
Notes
Standard-track 2L HCL for BRAF-V600E classic HCL. Drug entity for vemurafenib NOT yet in KB drugs/ — flagged for promotion when broader BRAF coverage opens. UA access barrier: vemurafenib registered for melanoma but not separately НСЗУ-funded for HCL. BRAF-WT HCL-variant routes to alternative algorithm.
Used By
Algorithms
ALGO-HCL-2L- ALGO-HCL-2L